New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:59 EDTGEVASynageva should be bought at current levels, says RW Baird
Baird said their investment thesis for Synageva remains unchanged following its successful display at the WORLD symposium last month. The firm recommends purchase at current levels as the company heads into an important value-creating period which includes potential pivotal data for a lead compound and the beginning of clinical trials for SBC-103. Shares are Outperform rated with a $107 price target.
News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
10:00 EDTGEVAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:28 EDTGEVASynageva downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
February 26, 2015
16:48 EDTGEVASynageva sees FY15 operating expenses $280M-$25M
Subscribe for More Information
16:48 EDTGEVASynageva reports Q4 EPS ($1.73), consensus ($1.71)
Subscribe for More Information
February 23, 2015
08:09 EDTGEVASynageva announces FDA accepts accepts BLA filing for Kanuma
Subscribe for More Information
07:22 EDTGEVASunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use